دسترسی یکساله به بیش از ۵۰۰ ژورنال روز جهان موجود در سامانه
-
http://medilib.ir
- ﻣﺪﺕ ﺯﻣﺎﻥ : 365 ﺭﻭﺯ
قیمت : 3,800,000 تومان- قیمت ویژه : 1,900,000تومان
Leptomeningeal Metastasis in the Era of CNS-Penetrant Tyrosine Kinase Inhibitor Therapy.
Jeng, Mark Y. MD, PhD 1; Yu, Helena A. MD 1,,
doi : 10.1200/JCO.24.01061
Volume 42(23) pgs. 2727-2838 August 10, 2024
Role of Minimally Invasive Techniques in the Management of Early-Stage Carcinoma of the Uterine Cervix.
Bercow, Alexandra MD 1; del Carmen, Marcela G. MD, MPH 1; Rauh-Hain, J. Alejandro MD, MPH 2,; Melamed, Alexander MD, MPH 1,,
doi : 10.1200/JCO.24.00656
Next-Generation Molecular Residual Disease Assays: Do We Have the Tools to Evaluate Them Properly?.
Stetson, Dan MS 1,; Labrousse, Paul MS 1,; Russell, Hugh PhD 1,; Shera, David ScD 2,; Abbosh, Chris MD, PhD 3,; Dougherty, Brian PhD 1,; Barrett, J. Carl PhD 1,; Hodgson, Darren PhD 3,; Hadfield, James PhD 4,,
doi : 10.1200/JCO.23.02301
LACC Trial: Final Analysis on Overall Survival Comparing Open Versus Minimally Invasive Radical Hysterectomy for Early-Stage Cervical Cancer.
Ramirez, Pedro T. MD 1,; Robledo, Kristy P. PhD 2; Frumovitz, Michael MD 3,; Pareja, Rene MD 4,5; Ribeiro, Reitan MD 6,; Lopez, Aldo MD 7; Yan, Xiaojian MD 8; Isla, David MD 9; Moretti, Renato MD 10; Bernardini, Marcus Q. MD 11,; Gebski, Val MStat 2; Asher, Rebecca MSc 2; Behan, Vanessa BSN 12; Coleman, Robert L. MD 13,; Obermair, Andreas MD 12,
doi : 10.1200/JCO.23.02335
Phase II Efficacy and Safety of 80 mg Osimertinib in Patients With Leptomeningeal Metastases Associated With Epidermal Growth Factor Receptor Mutation-Positive Non-Small Cell Lung Cancer (BLOSSOM).
Park, Sehhoon MD, PhD 1; Baldry, Richard BSc 2,; Jung, Hyun Ae MD, PhD 1,; Sun, Jong-Mu MD, PhD 1,; Lee, Se-Hoon MD, PhD 1,; Ahn, Jin Seok MD, PhD 1,; Kim, Yu Jung MD, PhD 3; Lee, Youngjoo MD, PhD 4,; Kim, Dong-Wan MD, PhD 5,; Kim, Sang-We MD, PhD 6; Lee, Ki Hyeong MD, PhD 7,; Lee, Won Jae MD 8; Choi, Jung Won MD, PhD 8; Chong, Kyuha MD, PhD 8; Lee, Jung-Il MD, PhD 8; Gwon, So-Hyeon BS 9; Son, Nak-Hoon PhD 9; Ahn, Myung-Ju MD, PhD 1,,
doi : 10.1200/JCO.24.00708
Minimal Residual Disease Status in Multiple Myeloma 1 Year After Autologous Hematopoietic Cell Transplantation and Lenalidomide Maintenance Are Associated With Long-Term Overall Survival.
Pasquini, Marcelo C. MD, MS 1,,; Wallace, Paul K. PhD 2,; Logan, Brent PhD 1; Kaur, Manmeet MPH 1; Tario, Joseph D. Jr, PhD 2; Howard, Alan PhD 3; Zhang, Yali MPH 2; Brunstein, Claudio MD, PhD 4,; Efebera, Yvonne MD 5,6,; Geller, Nancy PhD 7; Giralt, Sergio MD 8,; Hari, Parameswaran MD, MRCP 1,; Horowitz, Mary M. MD, MS 1,; Koreth, John MBBS, DPhil 9,; Krishnan, Amrita MD 10,; Landau, Heather MD 8,; Somlo, George MD, FACP 10; Shah, Nina MD 11,; Stadtmauer, Edward MD 12,; Vogl, Dan T. MD, MSCE 12,; Vesole, David H. MD 13,; McCarthy, Philip L. MD 2,; Hahn, Theresa PhD 2,
doi : 10.1200/JCO.23.00934
Phase I Trial of GD2.CART Cells Augmented With Constitutive Interleukin-7 Receptor for Treatment of High-Grade Pediatric CNS Tumors.
Lin, Frank Y. MD 1,2,; Stuckert, Austin MD 1; Tat, Candise MPH, BS 1; White, Mark PhD 1; Ruggieri, Lucia PA-C 3; Zhang, Huimin BS 4; Mehta, Birju MS 4; Lapteva, Natalia PhD 4,; Mei, Zhuyong MD 4; Major, Angela HT (ASCP) 5; Thakkar, Sachin PhD 1,4,; Shum, Thomas MD, PhD 4,6,; Parikh, Kathan BS 4; Wu, Meng-Fen MS 4,7; Lindsay, Holly B. MD, MS 8,; Scherer, Lauren MD 1; Shekar, Meghan MD 1; Baxter, Patricia MD, MBA 1,2,; Wang, Tao PhD 2,4,7; Grilley, Bambi RPh, RAC, CIP CCRC, CCRP 1,4,; Moeller, Karen MD 9; Hicks, John MD, DDS, MS, PhD 5; Roy, Angshumoy MBBS, PhD 2,5; Anastas, Jamie PhD 3; Malbari, Fatema MD 10; Aldave, Guillermo MD, PhD 3; Chintagumpala, Murali MD 1,2; Blaney, Susan MD 1,2; Parsons, D. Williams MD, PhD 1,2,; Brenner, Malcolm K. MD, PhD 1,2,4,7,; Heslop, Helen E. MD, DSc 1,2,4,7,; Rooney, Cliona M. PhD 1,2,4,; Omer, Bilal MD 1,2,4,
doi : 10.1200/JCO.23.02019
Olanzapine Plus Triple Antiemetic Therapy for the Prevention of Carboplatin-Induced Nausea and Vomiting: A Randomized, Double-Blind, Placebo-Controlled Phase III Trial.
Inui, Naoki MD, PhD 1,2,,; Suzuki, Takahito MD, PhD 1; Tanaka, Kazuki MD, PhD 1,3; Karayama, Masato MD, PhD 1,; Inoue, Yusuke MD, PhD 1; Mori, Kazutaka PhD 4,; Yasui, Hideki MD, PhD 1; Hozumi, Hironao MD, PhD 1,; Suzuki, Yuzo MD, PhD 1; Furuhashi, Kazuki MD, PhD 1; Fujisawa, Tomoyuki MD, PhD 1; Matsuura, Shun MD, PhD 3; Nishimoto, Koji MD, PhD 5,; Matsui, Takashi MD, PhD 6; Asada, Kazuhiro MD, PhD 7,; Hashimoto, Dai MD, PhD 8; Fujii, Masato MD, PhD 9; Niwa, Mitsuru MD, PhD 10; Uehara, Masahiro MD, PhD 11,; Matsuda, Hiroyuki MD, PhD 12; Koda, Keigo MD 13; Ikeda, Masaki MD, PhD 14; Inami, Nao MD 4; Tamiya, Yutaro MD, PhD 15,; Kato, Masato MD, PhD 16,; Nakano, Hideki MD, PhD 17; Mino, Yasuaki PhD 18,; Enomoto, Noriyuki MD, PhD 1,; Suda, Takafumi MD, PhD 1
doi : 10.1200/JCO.24.00278
Patient-Reported Outcomes From the Phase III HIMALAYA Study of Tremelimumab Plus Durvalumab in Unresectable Hepatocellular Carcinoma.
Sangro, Bruno MD, PhD 1,,; Galle, Peter R. MD, PhD 2,; Kelley, Robin Kate MD 3,; Charoentum, Chaiyut MD 4,; De Toni, Enrico N. MD, PhD 5,; Ostapenko, Yurii MD 6; Heo, Jeong MD, PhD 7,; Cheng, Ann-Lii MD, PhD 8,; Wilson Woods, Andrea MFA 9,; Gupta, Charu MSc 10,; Abraham, Jayne PhD 11,; McCoy, Carrie L. MD 12,; Patel, Nikunj PharmD 12,; Negro, Alejandra PhD 12,; Vogel, Arndt MD, PhD 13,14,; Abou-Alfa, Ghassan K. MD, MBA 15,16,
doi : 10.1200/JCO.23.01462
Bempegaldesleukin Plus Nivolumab Versus Sunitinib or Cabozantinib in Previously Untreated Advanced Clear Cell Renal Cell Carcinoma: A Phase III Randomized Study (PIVOT-09).
Tannir, Nizar M. MD, FACP 1,,; Formiga, Maria Nirvana MD, PhD 2; Penkov, Konstantin MD 3,; Kislov, Nikolay MD 4; Vasiliev, Aleksandr MD 5; Gunnar Skare, Nils MD 6,; Hong, Walter MD 7; Dai, Stanley MSc, BSc 7,; Tang, Lily PhD 7,; Qureshi, Anila MD, MPH 8,; Zalevsky, Jonathan PhD 7,; Tagliaferri, Mary A. MD 7,; George, Daniel MD 9,; Agarwal, Neeraj MD, FASCO 10,; Pal, Sumanta MD, FASCO 11,; Marathe, Omkar MD; Curti, Brendan MD; Hussain, Arif MD; Bilen, Mehmet Asim MD; Pal, Sumanta Kumar MD
doi : 10.1200/JCO.23.02082
Final Results of RIGHT Choice: Ribociclib Plus Endocrine Therapy Versus Combination Chemotherapy in Premenopausal Women With Clinically Aggressive Hormone Receptor-Positive/Human Epidermal Growth Factor Receptor 2-Negative Advanced Breast Cancer.
Lu, Yen-Shen MD, PhD 1,; Mahidin, Eznal Izwadi Bin Mohd MD 2; Azim, Hamdy MD 3,; Eralp, Yesim MD 4,; Yap, Yoon Sim MD, PhD 5,; Im, Seock-Ah MD, PhD 6,; Rihani, Julie 7; Gokmen, Erhan MD, PhD 8,; El Bastawisy, Ahmed MD 9,; Karadurmus, Nuri MD 10; Lim, Yueh Ni MD 11,; Lim, Chun Sen MD 12; Duc, Le Thanh MD 13
doi : 10.1200/JCO.24.00144
Fertility Preservation and Assisted Reproduction in Patients With Breast Cancer Interrupting Adjuvant Endocrine Therapy to Attempt Pregnancy.
Azim, Hatem A. Jr MD, PhD 1,2,,; Niman, Samuel M. MS 3,4; Partridge, Ann H. MD, MPH 5,6,; Demeestere, Isabelle MD, PhD 7,8,; Ruggeri, Monica 9; Colleoni, Marco MD 10,; Saura, Cristina MD, PhD 11,12,; Shimizu, Chikako MD 13,; Saetersdal, Anna B. MD 14,; Kroep, Judith R. MD, PhD 15,16,; Mailliez, Audrey 17,; Warner, Ellen MD 18,19; Borges, Virginia F. MD 20,; Amant, Frederic MD 21,22,23,; Gombos, Andrea MD 24,; Kataoka, Akemi MD 25; Rousset-Jablonski, Christine MD, PhD 26,; Borstnar, Simona MD, PhD 27,; Takei, Junko MD 28,; Lee, Jeong Eon MD, PhD 29,30; Walshe, Janice M. MD 31,32,33,; Ruiz-Borrego, Manuel MD 34,35,; Moore, Halle C.F. MD 36,; Saunders, Christobel MD 37,38; Bjelic-Radisic, Vesna MD, PhD 39,40,41,; Susnjar, Snezana MD 42,; Cardoso, Fatima MD 43,; Klar, Natalie J. MD 44; Spanic, Tanja PhD 45,; Ruddy, Kathryn MD, MPH 46,; Piccart, Martine MD, PhD 24,; Korde, Larissa A. MD, MPH 47; Goldhirsch, Aron MD +,48,49; Gelber, Richard D. PhD 3,4,6,50,51,; Pagani, Olivia MD 52,53,54,; Peccatori, Fedro A. MD, PhD 55
doi : 10.1200/JCO.23.02292
Selecting Patients With Oropharyngeal Cancer for Lower Dose Radiation.
Garden, Adam S. MD
doi : 10.1200/JCO.24.00395
Reply to A.S. Garden.
Lee, Nancy Y. MD, FASTRO; Sherman, Eric J. MD; Riaz, Nadeem MD, MSc
doi : 10.1200/JCO.24.00561
Erratum: Neoadjuvant Chemotherapy in High-Grade Myxoid Liposarcoma: Results of the Expanded Cohort of a Randomized Trial From Italian (ISG), Spanish (GEIS), French (FSG), and Polish Sarcoma Groups (PSG).
doi : 10.1200/JCO-24-01287
